The clinical impact of rifampicin-based anti-TB therapy and tenofovir alafenamide-containing ARV regimen drug Interaction in people living with HIV: Case series report

People living with HIV (PLWH) are prone to developing tuberculosis (TB). Since tenofovir alafenamide (TAF) is the recommended tenofovir (TFV) prodrug and rifampicin is a key component of TB therapy, thus complicating HIV and TB coinfection management. However, there is little data regarding the impa...

Full description

Saved in:
Bibliographic Details
Published inJournal of infection and public health Vol. 16; no. 12; pp. 2026 - 2030
Main Authors Mohzari, Yahya Ali, Musawa, Mohammed AL, Alrashed, Ahmad, Zaeri, Bandar, Damfu, Nader, Cahusac, Peter, Alwafai, Sana, Alamer, Ahmad, Almulhim, Abdulaziz
Format Journal Article
LanguageEnglish
Published Elsevier Ltd 01.12.2023
Elsevier
Subjects
Drug-drug interaction
HIV
Rifampicin-based anti-TB therapy
TAF-containing ARV regimen
Tuberculosis
Viral load suppression
Rifampicin-based anti-TB therapy
Viral load suppression
Tuberculosis
HIV
Drug-drug interaction
TAF-containing ARV regimen
Online AccessGet full text

Cover

Abstract People living with HIV (PLWH) are prone to developing tuberculosis (TB). Since tenofovir alafenamide (TAF) is the recommended tenofovir (TFV) prodrug and rifampicin is a key component of TB therapy, thus complicating HIV and TB coinfection management. However, there is little data regarding the impact of this drug-drug Interaction in PLWH, which makes health care providers reluctant to prescribe them together. This was an observational, retrospective case series carried out at King Faisal Specialist Hospital & Research Center (KFSH&RC), Jeddah, Saudi Arabia. PLWH (≥18 years old) who received the TAF-containing ARV regimen and rifampicin-based anti-TB therapy together for ≥ 4 weeks were included. The objective of this study was to report the clinical impact of this drug-drug interaction (rifampicin + TAF-containing antiretroviral (ARV) regimen) on HIV viral load control in PLWH. A total of 7 PLWH who met the inclusion criteria, 5 (71 %) out of 7, were males. All patients received dolutegravir 50 mg twice daily (DTG) plus the combination of TAF 25 mg and emtricitabine 200 mg (FTC) once daily as their ARV regimen. Four patients had suppressed viral load levels at baseline, which was maintained throughout TB treatment. Three patients had unsuppressed viral load levels at baseline and attained viral load suppression throughout the TB treatment course Overall, the TAF-containing ARV regimen maintained it's efficacy in presence of rifampicin.
AbstractList People living with HIV (PLWH) are prone to developing tuberculosis (TB). Since tenofovir alafenamide (TAF) is the recommended tenofovir (TFV) prodrug and rifampicin is a key component of TB therapy, thus complicating HIV and TB coinfection management. However, there is little data regarding the impact of this drug-drug Interaction in PLWH, which makes health care providers reluctant to prescribe them together. This was an observational, retrospective case series carried out at King Faisal Specialist Hospital & Research Center (KFSH&RC), Jeddah, Saudi Arabia. PLWH (≥18 years old) who received the TAF-containing ARV regimen and rifampicin-based anti-TB therapy together for ≥ 4 weeks were included. The objective of this study was to report the clinical impact of this drug-drug interaction (rifampicin + TAF-containing antiretroviral (ARV) regimen) on HIV viral load control in PLWH. A total of 7 PLWH who met the inclusion criteria, 5 (71 %) out of 7, were males. All patients received dolutegravir 50 mg twice daily (DTG) plus the combination of TAF 25 mg and emtricitabine 200 mg (FTC) once daily as their ARV regimen. Four patients had suppressed viral load levels at baseline, which was maintained throughout TB treatment. Three patients had unsuppressed viral load levels at baseline and attained viral load suppression throughout the TB treatment course Overall, the TAF-containing ARV regimen maintained it's efficacy in presence of rifampicin.
BACKGROUNDPeople living with HIV (PLWH) are prone to developing tuberculosis (TB). Since tenofovir alafenamide (TAF) is the recommended tenofovir (TFV) prodrug and rifampicin is a key component of TB therapy, thus complicating HIV and TB coinfection management. However, there is little data regarding the impact of this drug-drug Interaction in PLWH, which makes health care providers reluctant to prescribe them together.METHODSThis was an observational, retrospective case series carried out at King Faisal Specialist Hospital & Research Center (KFSH&RC), Jeddah, Saudi Arabia. PLWH (≥18 years old) who received the TAF-containing ARV regimen and rifampicin-based anti-TB therapy together for ≥ 4 weeks were included. The objective of this study was to report the clinical impact of this drug-drug interaction (rifampicin + TAF-containing antiretroviral (ARV) regimen) on HIV viral load control in PLWH.RESULTSA total of 7 PLWH who met the inclusion criteria, 5 (71 %) out of 7, were males. All patients received dolutegravir 50 mg twice daily (DTG) plus the combination of TAF 25 mg and emtricitabine 200 mg (FTC) once daily as their ARV regimen. Four patients had suppressed viral load levels at baseline, which was maintained throughout TB treatment. Three patients had unsuppressed viral load levels at baseline and attained viral load suppression throughout the TB treatment course CONCLUSION: Overall, the TAF-containing ARV regimen maintained it's efficacy in presence of rifampicin.
Background: People living with HIV (PLWH) are prone to developing tuberculosis (TB). Since tenofovir alafenamide (TAF) is the recommended tenofovir (TFV) prodrug and rifampicin is a key component of TB therapy, thus complicating HIV and TB coinfection management. However, there is little data regarding the impact of this drug-drug Interaction in PLWH, which makes health care providers reluctant to prescribe them together. Methods: This was an observational, retrospective case series carried out at King Faisal Specialist Hospital & Research Center (KFSH&RC), Jeddah, Saudi Arabia. PLWH (≥18 years old) who received the TAF-containing ARV regimen and rifampicin-based anti-TB therapy together for ≥ 4 weeks were included. The objective of this study was to report the clinical impact of this drug-drug interaction (rifampicin + TAF-containing antiretroviral (ARV) regimen) on HIV viral load control in PLWH. Results: A total of 7 PLWH who met the inclusion criteria, 5 (71 %) out of 7, were males. All patients received dolutegravir 50 mg twice daily (DTG) plus the combination of TAF 25 mg and emtricitabine 200 mg (FTC) once daily as their ARV regimen. Four patients had suppressed viral load levels at baseline, which was maintained throughout TB treatment. Three patients had unsuppressed viral load levels at baseline and attained viral load suppression throughout the TB treatment course Conclusion: Overall, the TAF-containing ARV regimen maintained it's efficacy in presence of rifampicin.
Author Mohzari, Yahya Ali
Alwafai, Sana
Almulhim, Abdulaziz
Cahusac, Peter
Zaeri, Bandar
Alamer, Ahmad
Musawa, Mohammed AL
Damfu, Nader
Alrashed, Ahmad
Author_xml – sequence: 1
  givenname: Yahya Ali
  surname: Mohzari
  fullname: Mohzari, Yahya Ali
  organization: Division of Pharmaceutical Care, Clinical Pharmacy Section, King Saud Medical City, Riyadh, Saudi Arabia
– sequence: 2
  givenname: Mohammed AL
  surname: Musawa
  fullname: Musawa, Mohammed AL
  organization: Division of Pharmaceutical Care, King Faisal Specialist Hospital, and Research Center, Jeddah, Saudi Arabia
– sequence: 3
  givenname: Ahmad
  surname: Alrashed
  fullname: Alrashed, Ahmad
  organization: Department of Pharmacy, King Fahad Medical City, Riyadh, Saudi Arabia
– sequence: 4
  givenname: Bandar
  surname: Zaeri
  fullname: Zaeri, Bandar
  organization: Department of Infectious Diseases, King Saud Medical City, Riyadh, Saudi Arabia
– sequence: 5
  givenname: Nader
  surname: Damfu
  fullname: Damfu, Nader
  organization: Division of Pharmaceutical Care, King Abdulaziz Medical City, Jeddah, Saudi Arabia
– sequence: 6
  givenname: Peter
  surname: Cahusac
  fullname: Cahusac, Peter
  organization: Department of Pharmacology and Biostatistics/Comparative Medicine, Alfaisal University College of Medicine and King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia
– sequence: 7
  givenname: Sana
  surname: Alwafai
  fullname: Alwafai, Sana
  organization: Department of Pharmacy Practice, Batterjee Medical College, Jeddah, Saudi Arabia
– sequence: 8
  givenname: Ahmad
  orcidid: 0000-0002-2091-1376
  surname: Alamer
  fullname: Alamer, Ahmad
  organization: Department of Clinical Pharmacy, Prince Sattam bin Abdulaziz University, Alkharj, Saudi Arabia
– sequence: 9
  givenname: Abdulaziz
  surname: Almulhim
  fullname: Almulhim, Abdulaziz
  email: asaalmulhim@kfu.du.sa
  organization: Department of Pharmacy Practice, King Faisal University, Alahsa, Saudi Arabia
BookMark eNp9kc1uEzEUhUeoSLSFF2DlJZsJ9tjzh9iUqNBIlZBQqNhZHvs6udGMPdhOUN-GJc_Bk-EhqEtWto_O-a51z1Vx4byDonjN6IpR1rw9rA4471cVrXgWVpSxZ8Ul69qmpLz-dvF0F-xFcRXjgdKG16K_LH5t90D0iA61GglOs9KJeEsCWjXNqNGVg4pgiHIJy-0HkvYQ1PyY34YkcN76EwaiRmXBqQkNlNq7pDLQ7cjNlwcSYIcTOGLCcUc2LuW4Tujd75_oyAx-HoGMeFrsPzDtyd3m4R1Z55kkQkCIGTD7kF4Wz60aI7z6d14XXz_ebtd35f3nT5v1zX2pheCp1IpTY41hhvbWNBXn2vTC9NpwxnraMc4G3tO6so0RBpq-ZbbiaqibQXc8r--62Jy5xquDnANOKjxKr1D-FXzYSRUS6hFkXXVQUUEH0YLouRig0V3f2qbtWa9am1lvzqw5-O9HiElOGDWMo3Lgj1FWXcfrrmlFm63V2aqDjzGAfRrNqFwqlge5VCyXihctV5xD788hyAs5IQQZNYLTYDCATvnH-L_4H5iltCQ
CitedBy_id crossref_primary_10_1080_17512433_2024_2317954
crossref_primary_10_3390_v16040494
Cites_doi 10.1515/folmed-2017-0052
10.1097/QAI.0000000000001350
10.1093/jac/dkz068
10.2165/00003088-200342090-00003
10.1056/NEJMoa0905848
10.1097/QAI.0000000000000940
10.1097/QAI.0000000000001699
10.1056/NEJMoa1014181
10.1128/AAC.00251-06
10.1016/j.coph.2010.04.011
10.1128/AAC.01089-12
10.1097/QAI.0000000000000225
10.1016/S0140-6736(15)60616-X
10.1056/NEJMoa1013607
10.1172/JCI6663
10.1007/s40262-018-00732-2
10.1093/cid/ciw376
10.1016/S1473-3099(15)00348-5
10.1053/j.ajkd.2011.01.022
10.1056/NEJMoa1013911
10.1097/FTD.0000000000000108
ContentType Journal Article
Copyright 2023 The Author(s)
Copyright_xml – notice: 2023 The Author(s)
DBID 6I.
AAFTH
AAYXX
CITATION
7X8
DOA
DOI 10.1016/j.jiph.2023.10.011
DatabaseName ScienceDirect Open Access Titles
Elsevier:ScienceDirect:Open Access
CrossRef
MEDLINE - Academic
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1876-035X
EndPage 2030
ExternalDocumentID oai_doaj_org_article_528e2040b47e4934be6c897f67919a7f
10_1016_j_jiph_2023_10_011
S1876034123003386
GroupedDBID ---
--K
.1-
.FO
.~1
0R~
0SF
1B1
1P~
1~.
4.4
457
4G.
53G
5GY
5VS
6I.
7-5
71M
8P~
AACTN
AAEDW
AAFTH
AAIKJ
AALRI
AAQFI
AAXUO
ABBQC
ABMAC
ACGFS
ADBBV
ADEZE
ADMUD
AEKER
AENEX
AEVXI
AFKWA
AFRHN
AFTJW
AGHFR
AGYEJ
AITUG
AJOXV
AJRQY
AJUYK
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
BCNDV
BLXMC
DU5
EBS
EFLBG
EJD
EP2
EP3
F5P
FDB
FEDTE
FIRID
FNPLU
GBLVA
GROUPED_DOAJ
HVGLF
HX~
HZ~
J1W
LCYCR
M41
MO0
N9A
NCXOZ
O-L
O9-
OAUVE
OD-
OK1
OO.
OZT
P-8
P-9
P2P
PC.
Q38
RIG
ROL
SDF
SEL
SES
SSZ
W2D
Z5R
AAYXX
ADVLN
AKRWK
CITATION
7X8
ID FETCH-LOGICAL-c443t-ca30dfdd1d09fd6233cd94d9cd311908131b39052f6d4de6971f23ab56bc83023
IEDL.DBID .~1
ISSN 1876-0341
IngestDate Thu Jul 04 21:09:50 EDT 2024
Wed Jul 24 15:28:01 EDT 2024
Mon Aug 26 01:32:32 EDT 2024
Fri Feb 23 02:34:57 EST 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 12
Keywords Rifampicin-based anti-TB therapy
Viral load suppression
Tuberculosis
HIV
Drug-drug interaction
TAF-containing ARV regimen
Language English
License This is an open access article under the CC BY-NC-ND license.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c443t-ca30dfdd1d09fd6233cd94d9cd311908131b39052f6d4de6971f23ab56bc83023
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-2091-1376
OpenAccessLink https://www.sciencedirect.com/science/article/pii/S1876034123003386
PQID 2883586747
PQPubID 23479
PageCount 5
ParticipantIDs doaj_primary_oai_doaj_org_article_528e2040b47e4934be6c897f67919a7f
proquest_miscellaneous_2883586747
crossref_primary_10_1016_j_jiph_2023_10_011
elsevier_sciencedirect_doi_10_1016_j_jiph_2023_10_011
PublicationCentury 2000
PublicationDate December 2023
2023-12-00
20231201
2023-12-01
PublicationDateYYYYMMDD 2023-12-01
PublicationDate_xml – month: 12
  year: 2023
  text: December 2023
PublicationDecade 2020
PublicationTitle Journal of infection and public health
PublicationYear 2023
Publisher Elsevier Ltd
Elsevier
Publisher_xml – name: Elsevier Ltd
– name: Elsevier
References Wohl, Oka, Clumeck, Clarke, Brinson, Stephens (bib20) 2016; 72
Niemi, Backman, Fromm, Neuvonen, Kivistö (bib24) 2003; 42
Nahid, Dorman, Alipanah, Barry, Brozek, Cattamanchi (bib11) 2016; 63
Lepist, Phan, Roy, Tong, Maclennan, Murray (bib21) 2012; 56
bib14
Abdool Karim, Naidoo, Grobler, Padayatchi, Baxter, Gray (bib5) 2011; 365
bib12
Sax, Zolopa, Brar, Elion, Ortiz, Post (bib15) 2014; 67
Begley, Das, Zhong, Ling, Kearney, Custodio (bib22) 2018; 78
bib27
Arribas, Thompson, Sax, Haas, McDonald, Wohl (bib18) 2017; 75
Ray, Cihlar, Robinson, Tong, Vela, Fuller (bib16) 2006; 50
Anon. Tuberculosis. WHO; 2022.
Sax, Wohl, Yin, Post, DeJesus, Saag (bib17) 2015; 385
Mills, Arribas, Andrade-Villanueva, DiPerri, Van Lunzen, Koenig (bib19) 2016; 16
bib25
Havlir, Kendall, Ive, Kumwenda, Swindells, Qasba (bib7) 2011; 365
Abdool Karim, Naidoo, Grobler, Padayatchi, Baxter, Gray (bib4) 2010; 362
Stoycheva, Vatev, Georgieva, Dineva, Atanasova, Popova (bib2) 2017; 59
Blanc, Sok, Laureillard, Borand, Rekacewicz, Nerrienet (bib6) 2011; 365
Greiner, Eichelbaum, Fritz, Kreichgauer, von Richter, Zundler (bib23) 1999; 104
De Clercq (bib9) 2010; 10
Cerrone, Alfarisi, Neary, Marzinke, Parsons, Owen (bib26) 2019; 74
Anon (bib1) 2019
Hall, Hendry, Nitsch, Connolly (bib13) 2011; 57
Van Beek, Ter Heine, Keizer, Magis-Escurra, Aarnoutse, Svensson (bib8) 2019; 58
Semvua, Kibiki, Kisanga, Boeree, Burger, Aarnoutse (bib10) 2015; 37
Sax (10.1016/j.jiph.2023.10.011_bib17) 2015; 385
Cerrone (10.1016/j.jiph.2023.10.011_bib26) 2019; 74
Blanc (10.1016/j.jiph.2023.10.011_bib6) 2011; 365
Arribas (10.1016/j.jiph.2023.10.011_bib18) 2017; 75
Sax (10.1016/j.jiph.2023.10.011_bib15) 2014; 67
Ray (10.1016/j.jiph.2023.10.011_bib16) 2006; 50
Niemi (10.1016/j.jiph.2023.10.011_bib24) 2003; 42
Wohl (10.1016/j.jiph.2023.10.011_bib20) 2016; 72
Mills (10.1016/j.jiph.2023.10.011_bib19) 2016; 16
Lepist (10.1016/j.jiph.2023.10.011_bib21) 2012; 56
Semvua (10.1016/j.jiph.2023.10.011_bib10) 2015; 37
Hall (10.1016/j.jiph.2023.10.011_bib13) 2011; 57
Greiner (10.1016/j.jiph.2023.10.011_bib23) 1999; 104
Havlir (10.1016/j.jiph.2023.10.011_bib7) 2011; 365
Van Beek (10.1016/j.jiph.2023.10.011_bib8) 2019; 58
Abdool Karim (10.1016/j.jiph.2023.10.011_bib5) 2011; 365
10.1016/j.jiph.2023.10.011_bib3
Nahid (10.1016/j.jiph.2023.10.011_bib11) 2016; 63
De Clercq (10.1016/j.jiph.2023.10.011_bib9) 2010; 10
Anon (10.1016/j.jiph.2023.10.011_bib1) 2019
Abdool Karim (10.1016/j.jiph.2023.10.011_bib4) 2010; 362
Stoycheva (10.1016/j.jiph.2023.10.011_bib2) 2017; 59
Begley (10.1016/j.jiph.2023.10.011_bib22) 2018; 78
References_xml – volume: 72
  start-page: 58
  year: 2016
  end-page: 64
  ident: bib20
  article-title: Brief report: a randomized, double-blind comparison of tenofovir alafenamide versus tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine for initial HIV-1 treatment: week 96 results
  publication-title: J Acquir Immune Defic Syndr
  contributor:
    fullname: Stephens
– volume: 37
  start-page: 22
  year: 2015
  end-page: 32
  ident: bib10
  article-title: Pharmacological interactions between rifampicin and antiretroviral drugs: challenges and research priorities for resource-limited settings
  publication-title: Ther Drug Monit
  contributor:
    fullname: Aarnoutse
– volume: 385
  start-page: 2606
  year: 2015
  end-page: 2615
  ident: bib17
  article-title: Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials
  publication-title: Lancet
  contributor:
    fullname: Saag
– volume: 75
  start-page: 211
  year: 2017
  end-page: 218
  ident: bib18
  article-title: Brief report: randomized, double-blind comparison of tenofovir alafenamide (TAF) vs tenofovir disoproxil fumarate (TDF), each coformulated with elvitegravir, cobicistat, and emtricitabine (E/C/F) for initial HIV-1 treatment: week 144 results
  publication-title: J Acquir Immune Defic Syndr
  contributor:
    fullname: Wohl
– volume: 58
  start-page: 815
  year: 2019
  end-page: 826
  ident: bib8
  article-title: Personalized tuberculosis treatment through model-informed dosing of rifampicin
  publication-title: Clin Pharmacokinet
  contributor:
    fullname: Svensson
– volume: 74
  start-page: 1670
  year: 2019
  end-page: 1678
  ident: bib26
  article-title: Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamide
  publication-title: J Antimicrob Chemother
  contributor:
    fullname: Owen
– volume: 59
  start-page: 454
  year: 2017
  end-page: 460
  ident: bib2
  article-title: Lethality among patients with HIV/AIDS monitored in the clinic of infectious diseases in St George University Hospital, Plovdiv, 2010–2014
  publication-title: Folia Med
  contributor:
    fullname: Popova
– volume: 16
  start-page: 43
  year: 2016
  end-page: 52
  ident: bib19
  article-title: Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study
  publication-title: Lancet Infect Dis
  contributor:
    fullname: Koenig
– volume: 50
  start-page: 3297
  year: 2006
  end-page: 3304
  ident: bib16
  article-title: Mechanism of active renal tubular efflux of tenofovir
  publication-title: Antimicrob Agents Chemother
  contributor:
    fullname: Fuller
– volume: 104
  start-page: 147
  year: 1999
  end-page: 153
  ident: bib23
  article-title: The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin
  publication-title: J Clin Investig
  contributor:
    fullname: Zundler
– year: 2019
  ident: bib1
  article-title: HIV and tuberculosis: a potentially deadly combination
  publication-title: Contagionlive
  contributor:
    fullname: Anon
– volume: 365
  start-page: 1471
  year: 2011
  end-page: 1481
  ident: bib6
  article-title: Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis
  publication-title: N Engl J Med
  contributor:
    fullname: Nerrienet
– ident: bib14
– volume: 56
  start-page: 5409
  year: 2012
  end-page: 5413
  ident: bib21
  article-title: Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitro
  publication-title: Antimicrob Agents Chemother
  contributor:
    fullname: Murray
– volume: 362
  start-page: 697
  year: 2010
  end-page: 706
  ident: bib4
  article-title: Timing of initiation of antiretroviral drugs during tuberculosis therapy
  publication-title: N Engl J Med
  contributor:
    fullname: Gray
– volume: 365
  start-page: 1482
  year: 2011
  end-page: 1491
  ident: bib7
  article-title: Timing of antiretroviral therapy for HIV-1 infection and tuberculosis
  publication-title: N Engl J Med
  contributor:
    fullname: Qasba
– ident: bib12
– volume: 42
  start-page: 819
  year: 2003
  end-page: 850
  ident: bib24
  article-title: Pharmacokinetic interactions with rifampicin: clinical relevance
  publication-title: Clin Pharmacokinet
  contributor:
    fullname: Kivistö
– volume: 57
  start-page: 773
  year: 2011
  end-page: 780
  ident: bib13
  article-title: Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence
  publication-title: Am J Kidney Dis
  contributor:
    fullname: Connolly
– volume: 67
  start-page: 52
  year: 2014
  end-page: 58
  ident: bib15
  article-title: Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study
  publication-title: J Acquir Immune Defic Syndr
  contributor:
    fullname: Post
– volume: 78
  start-page: 465
  year: 2018
  end-page: 472
  ident: bib22
  article-title: Pharmacokinetics of tenofovir alafenamide when coadministered with other HIV antiretrovirals
  publication-title: J Acquir Immune Defic Syndr
  contributor:
    fullname: Custodio
– ident: bib25
– ident: bib27
– volume: 365
  start-page: 1492
  year: 2011
  end-page: 1501
  ident: bib5
  article-title: Integration of antiretroviral therapy with tuberculosis treatment
  publication-title: N Engl J Med
  contributor:
    fullname: Gray
– volume: 63
  start-page: e147
  year: 2016
  end-page: e195
  ident: bib11
  article-title: Official American thoracic society/centers for disease control and prevention/infectious diseases society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis
  publication-title: Clin Infect Dis
  contributor:
    fullname: Cattamanchi
– volume: 10
  start-page: 507
  year: 2010
  end-page: 515
  ident: bib9
  article-title: Antiretroviral drugs
  publication-title: Curr Opin Pharmacol
  contributor:
    fullname: De Clercq
– volume: 59
  start-page: 454
  year: 2017
  ident: 10.1016/j.jiph.2023.10.011_bib2
  article-title: Lethality among patients with HIV/AIDS monitored in the clinic of infectious diseases in St George University Hospital, Plovdiv, 2010–2014
  publication-title: Folia Med
  doi: 10.1515/folmed-2017-0052
  contributor:
    fullname: Stoycheva
– volume: 75
  start-page: 211
  year: 2017
  ident: 10.1016/j.jiph.2023.10.011_bib18
  article-title: Brief report: randomized, double-blind comparison of tenofovir alafenamide (TAF) vs tenofovir disoproxil fumarate (TDF), each coformulated with elvitegravir, cobicistat, and emtricitabine (E/C/F) for initial HIV-1 treatment: week 144 results
  publication-title: J Acquir Immune Defic Syndr
  doi: 10.1097/QAI.0000000000001350
  contributor:
    fullname: Arribas
– volume: 74
  start-page: 1670
  year: 2019
  ident: 10.1016/j.jiph.2023.10.011_bib26
  article-title: Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamide
  publication-title: J Antimicrob Chemother
  doi: 10.1093/jac/dkz068
  contributor:
    fullname: Cerrone
– volume: 42
  start-page: 819
  year: 2003
  ident: 10.1016/j.jiph.2023.10.011_bib24
  article-title: Pharmacokinetic interactions with rifampicin: clinical relevance
  publication-title: Clin Pharmacokinet
  doi: 10.2165/00003088-200342090-00003
  contributor:
    fullname: Niemi
– volume: 362
  start-page: 697
  year: 2010
  ident: 10.1016/j.jiph.2023.10.011_bib4
  article-title: Timing of initiation of antiretroviral drugs during tuberculosis therapy
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa0905848
  contributor:
    fullname: Abdool Karim
– volume: 72
  start-page: 58
  year: 2016
  ident: 10.1016/j.jiph.2023.10.011_bib20
  article-title: Brief report: a randomized, double-blind comparison of tenofovir alafenamide versus tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine for initial HIV-1 treatment: week 96 results
  publication-title: J Acquir Immune Defic Syndr
  doi: 10.1097/QAI.0000000000000940
  contributor:
    fullname: Wohl
– volume: 78
  start-page: 465
  year: 2018
  ident: 10.1016/j.jiph.2023.10.011_bib22
  article-title: Pharmacokinetics of tenofovir alafenamide when coadministered with other HIV antiretrovirals
  publication-title: J Acquir Immune Defic Syndr
  doi: 10.1097/QAI.0000000000001699
  contributor:
    fullname: Begley
– volume: 365
  start-page: 1492
  year: 2011
  ident: 10.1016/j.jiph.2023.10.011_bib5
  article-title: Integration of antiretroviral therapy with tuberculosis treatment
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1014181
  contributor:
    fullname: Abdool Karim
– volume: 50
  start-page: 3297
  year: 2006
  ident: 10.1016/j.jiph.2023.10.011_bib16
  article-title: Mechanism of active renal tubular efflux of tenofovir
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.00251-06
  contributor:
    fullname: Ray
– ident: 10.1016/j.jiph.2023.10.011_bib3
– volume: 10
  start-page: 507
  year: 2010
  ident: 10.1016/j.jiph.2023.10.011_bib9
  article-title: Antiretroviral drugs
  publication-title: Curr Opin Pharmacol
  doi: 10.1016/j.coph.2010.04.011
  contributor:
    fullname: De Clercq
– volume: 56
  start-page: 5409
  year: 2012
  ident: 10.1016/j.jiph.2023.10.011_bib21
  article-title: Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitro
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.01089-12
  contributor:
    fullname: Lepist
– volume: 67
  start-page: 52
  year: 2014
  ident: 10.1016/j.jiph.2023.10.011_bib15
  article-title: Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study
  publication-title: J Acquir Immune Defic Syndr
  doi: 10.1097/QAI.0000000000000225
  contributor:
    fullname: Sax
– volume: 385
  start-page: 2606
  year: 2015
  ident: 10.1016/j.jiph.2023.10.011_bib17
  article-title: Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials
  publication-title: Lancet
  doi: 10.1016/S0140-6736(15)60616-X
  contributor:
    fullname: Sax
– volume: 365
  start-page: 1482
  year: 2011
  ident: 10.1016/j.jiph.2023.10.011_bib7
  article-title: Timing of antiretroviral therapy for HIV-1 infection and tuberculosis
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1013607
  contributor:
    fullname: Havlir
– volume: 104
  start-page: 147
  year: 1999
  ident: 10.1016/j.jiph.2023.10.011_bib23
  article-title: The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin
  publication-title: J Clin Investig
  doi: 10.1172/JCI6663
  contributor:
    fullname: Greiner
– volume: 58
  start-page: 815
  year: 2019
  ident: 10.1016/j.jiph.2023.10.011_bib8
  article-title: Personalized tuberculosis treatment through model-informed dosing of rifampicin
  publication-title: Clin Pharmacokinet
  doi: 10.1007/s40262-018-00732-2
  contributor:
    fullname: Van Beek
– volume: 63
  start-page: e147
  year: 2016
  ident: 10.1016/j.jiph.2023.10.011_bib11
  article-title: Official American thoracic society/centers for disease control and prevention/infectious diseases society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis
  publication-title: Clin Infect Dis
  doi: 10.1093/cid/ciw376
  contributor:
    fullname: Nahid
– volume: 16
  start-page: 43
  year: 2016
  ident: 10.1016/j.jiph.2023.10.011_bib19
  article-title: Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study
  publication-title: Lancet Infect Dis
  doi: 10.1016/S1473-3099(15)00348-5
  contributor:
    fullname: Mills
– year: 2019
  ident: 10.1016/j.jiph.2023.10.011_bib1
  article-title: HIV and tuberculosis: a potentially deadly combination
  publication-title: Contagionlive
  contributor:
    fullname: Anon
– volume: 57
  start-page: 773
  year: 2011
  ident: 10.1016/j.jiph.2023.10.011_bib13
  article-title: Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence
  publication-title: Am J Kidney Dis
  doi: 10.1053/j.ajkd.2011.01.022
  contributor:
    fullname: Hall
– volume: 365
  start-page: 1471
  year: 2011
  ident: 10.1016/j.jiph.2023.10.011_bib6
  article-title: Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1013911
  contributor:
    fullname: Blanc
– volume: 37
  start-page: 22
  year: 2015
  ident: 10.1016/j.jiph.2023.10.011_bib10
  article-title: Pharmacological interactions between rifampicin and antiretroviral drugs: challenges and research priorities for resource-limited settings
  publication-title: Ther Drug Monit
  doi: 10.1097/FTD.0000000000000108
  contributor:
    fullname: Semvua
SSID ssj0063549
Score 2.3453472
Snippet People living with HIV (PLWH) are prone to developing tuberculosis (TB). Since tenofovir alafenamide (TAF) is the recommended tenofovir (TFV) prodrug and...
BACKGROUNDPeople living with HIV (PLWH) are prone to developing tuberculosis (TB). Since tenofovir alafenamide (TAF) is the recommended tenofovir (TFV) prodrug...
Background: People living with HIV (PLWH) are prone to developing tuberculosis (TB). Since tenofovir alafenamide (TAF) is the recommended tenofovir (TFV)...
SourceID doaj
proquest
crossref
elsevier
SourceType Open Website
Aggregation Database
Publisher
StartPage 2026
SubjectTerms Drug-drug interaction
HIV
Rifampicin-based anti-TB therapy
TAF-containing ARV regimen
Tuberculosis
Viral load suppression
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQD4gL4imWRzVI3JBh_Uri3tqKakEqB9RWvUV2bKNUbbLa7iL13_TY38Ev60ycIMoBLhxjRbblGc9843kx9s46pVysLBo5peHaB8e9cJKLpEppotTGUu7w4ddicay_nJrT31p9UUxYLg-cD-6jkVWUyGlel1FbpX0smsqWqSitsK5Mg_QVZjKmsgxGLToAX4F3nc9RUI_pMjmy66xdkhtCqg8U1yXEHZU0VO6_o5n-kNGD4jl4xB6OiBF2804fs3uxe8LuH44-8afsBikNU4Ij5KxH6BOs2uQulvQTJ1UVAM-w5Ud7kFOurvA7ACLmPvU_2hW4c5cidacPkVP8eu4cAbvfToCaN1zEDsJq8x2GJ8ScDfHzuu0gh6DDeUsvE0DPurD4fLID-7gmEH_HS8iOiWfs-ODT0f6Cj_0XeKO1WvPGqXlIIYgwtykgTlJNsDrYJiiBOKISSnhl50amIugQC1uKJJXzpvANlRVTz9lW13fxBYPCRV-qppAhWd00waPZh3OXQVodo0sz9n4iQb3MZTbqKf7srCaC1UQwGkOCzdgeUenXn1QiexhAxqlHxqn_xTgzZiYa1yPayCgCp2r_uvjbiSFqvIrkX3Fd7DeXNTVuNlWBBtrL_7HBV-wBLZtjZ16zrfVqE98gAlr77YHZbwG50QRw
  priority: 102
  providerName: Directory of Open Access Journals
Title The clinical impact of rifampicin-based anti-TB therapy and tenofovir alafenamide-containing ARV regimen drug Interaction in people living with HIV: Case series report
URI https://dx.doi.org/10.1016/j.jiph.2023.10.011
https://search.proquest.com/docview/2883586747
https://doaj.org/article/528e2040b47e4934be6c897f67919a7f
Volume 16
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnR3LbtQw0Kp6QFwQT1Ee1SBxQ-6uH3mYW7uiWpDKAdqqt8iO7SpVm6zSXSQufAtHvoMvYyZOKi0HDhxjjezIM573g7G3xiplQ2nQyCkyrp233AkruYiqkFmQOjNUO3zyOV-e6U8X2cUOW0y1MJRWOfL-xNMHbj2uzMbbnK2aZvZV4EOeIxNGJXqOhha13dYojJCmD37cpXmgPB1UYALmBD0WzqQcr6tmRQEJqQ4ow0uILeE09PDfklF_cetBBB0_ZA9G3REO0-89YjuhfczunYzR8SfsF-IcplJHSPWP0EXom2hvVgTESWh5wNts-OkRpOKr7_jtAXXnLnbfmh7stY2B5tT7wCmTPc2QgMMv50BjHG5CC77fXMLgTEx1Eb9_Ni2kZHS4bshHAeTgheXH8_ewwDOBKD3cQgpRPGVnxx9OF0s-TmLgtdZqzWur5j56L_zcRI8ak6q90d7UXgnUKEqhhFNmnsmYe-1DbgoRpbIuy11NDcbUM7bbdm14ziC3wRWqzqWPRte1d2gA4t6Fl0aHYOMeezehoFqlhhvVlIl2VRHCKkIYrSHC9tgRYekOkpplDwtdf1mN1FJlsgwSmZXTRdBGaRfyujRFzAsjjC3wyGzCcbVFe7hV88_D30wEUeGjpEiLbUO3ua1ohHNW5miqvfjPvV-y-_SVEmdesd11vwmvUf1Zu_2BvvcH58Ef8iwGhA
link.rule.ids 315,786,790,870,2115,4521,27957,27958,45620
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NbtQwELZKkYAL4leU30HihtKNY8eJubUrqi10e4Bt1VvkxHaVqk1W6S4SF56FI8_BkzETJ5WWAweOcUZ25JnMjD3fzDD2ThshjMs1HnKyNJKlNVHJTRJxL7IkdYlMNeUOz4_V7ER-OkvPtth0zIUhWOWg-4NO77X1MDIZdnOyrOvJV44_coxKGJ3oGA9a6ha7Te489W_Y_XGD80CD2vvARB0R-ZA5E0BeF_WSIhKJ2CWIF-cb1qkv4r9hpP5S170NOnjA7g_OI-yF73vItlzziN2ZD-Hxx-wXMh3GXEcICZDQeuhqb66WRBSR1bKA21lHi30I2Vff8dkCOs-tb7_VHZhL4x01qrcuIih7aCIBe19Ogfo4XLkGbLc-h_42MSRG_P5ZNxDQ6HBZ0yUF0A0vzA5PP8AU1wQSdXcNIUbxhJ0cfFxMZ9HQiiGqpBSrqDIitt5abmPtLbpMorJaWl1ZwdGlyLngpdBxmnhlpXVKZ9wnwpSpKiuqMCaesu2mbdwzBsq4MhOVSqzXsqpsiSdAnDuziZbOGb_D3o8sKJah4kYxQtEuCmJYQQyjMWTYDtsnLt1QUrXsfqDtzotBXIo0yV2C2qqUmZNayNKpKteZV5nm2mS4ZDryuNgQPpyq_ufib0eBKPCvpFCLaVy7vi6oh3OaKzyrPf_Pud-wu7PF_Kg4Ojz-_ILdozcBRfOSba-6tXuFvtCqfN3L-h_1PAiv
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+clinical+impact+of+rifampicin-based+anti-TB+therapy+and+tenofovir+alafenamide-containing+ARV+regimen+drug+Interaction%C2%A0in+people+living+with+HIV%3A+Case+series+report&rft.jtitle=Journal+of+infection+and+public+health&rft.au=Mohzari%2C+Yahya+Ali&rft.au=Musawa%2C+Mohammed+AL&rft.au=Alrashed%2C+Ahmad&rft.au=Zaeri%2C+Bandar&rft.date=2023-12-01&rft.issn=1876-0341&rft.volume=16&rft.issue=12&rft.spage=2026&rft.epage=2030&rft_id=info:doi/10.1016%2Fj.jiph.2023.10.011&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_j_jiph_2023_10_011
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1876-0341&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1876-0341&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1876-0341&client=summon